Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

INDICATION VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). Contraindications Use of VYKAT XR is ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of Vykat for Prader-Willi syndrome, despite initial clinical trial challenges.

Soleno Therapeutics traded as high as $70.20 and last traded at $67.31, with a volume of 2375198 shares. The stock had previously closed at $48.97. SLNO has been the subject of several other reports.

The drug, a once-daily pill called Vykat XR, was developed by Soleno Therapeutics. “The approval of Vykat XR is a significant milestone for Soleno and, most importantly, for the PWS community ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...